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ABSTRACT 
Ezogabine, an antiepileptic drug used for treating partial epilepsies.  It is poorly soluble in water.  The dose ranges from 50 mg to 400 mg and 
the oral bioavailability is 60%.  The aim of this research work was to formulate and characterize nanosuspensions of ezogabine with an 
intention to enhance the oral bioavailability using 32 factorial design.   Nanosuspensions were prepared by the “bottom-up” nanoprecipitation 
method using 32 factorial design and evaluation for particle size, saturation solubility, zeta potential, entrapment efficiency, and in-vitro drug 
release was done.  The FTIR was used to confirm compatibility and to rule out any possible interactions between drug and carr iers.  The 
optimal nanosuspension was obtained with particle size of 510.4 nm, saturation solubility of 557 μg/ml, zeta potential of - 4.49 mV, entrapment 
efficiency of 96.82%, and in-vitro drug release of 100.14%.  Also, the optimal formulation was found to be stable in the accelerated conditions.  
Data of nanosuspensions were fit in to different equations and kinetic models and found to exhibit first order release kinetics with class II 
transport mechanism of diffusion.  The scanning electron microscopy studies showed elongated nanoparticles with porous surfac e.  The 
“Bottom up” method can be successfully employed to produce ezogabine nanosuspensions achieving reduced particle size and enhancing 
dissolution rate by increasing the saturation solubility and remained stable at 25 °C. 
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INTRODUCTION 
Among the total populace, the most predominant of the 
unfeigned neurological unhinge is epilepsy which is most 
feigning about 0.5 to 1%.  A seizure is a clinical denotation, 
ensuing about because of a remit sequence of unnatural 
extravagant or synchronous neuronal movement in the 
brain. Epilepsy is a brain unhinge described by an inveterate 
sensitivity to create epileptic seizures with optional 
neurobiological, intellectual, mental, and social outcomes.  
 
Fig. 1:  Chemical structure of Ezogabine 
Patients with epilepsy are at an expanded danger of 
untimely demise with a mortality danger of 1.2 to 9.3 of all 
reasons for demise and a 24% long term casualty rate. 1, 2 
Ezogabine deeds as a neuronal KCNQ/Kv7 potassium 
channel opener.  It is an antiepileptic drug practised for the 
intervention of partial epilepsies.  Its primary mechanism of 
action as a positive allosteric modulator of KCNQ2-5 ion 
channels defines ezogabine as the first neuronal potassium 
channel opener for the treatment of epilepsy.  KCNQ2-5 
channels are predominantly expressed in neurons and are 
important determinants of cellular excitability, as indicated 
by the occurrence of human genetic mutations in KCNQ 
channels that underlie inheritable disorders including, in the 
case of KCNQ2/3, the syndrome of benign familial neonatal 
convulsions. At present commercialized potassium channel 
opener is established completely in oral dosage frame. Be 
that as it may, elective and specifically, intranasal route may 
give more benefits when compared to oral route. The 
fallouts of oral route of potassium channel opener admits 
gastrointestinal disorderlinesses, urinary perturbs etc. 3 
Intranasal route conveyance is debated as a feasible and 
captivating route for versatile drugs. 4  
Common methodology for solvability melioration is 
micronization of medication. The process of micronization 
expands the dissolution rate the medication because of 
surface area expansion however it does not alter the 
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saturation solvability. 5 Another significant perspective is the 
expansion in saturation solvability. Additionally, as per 
Kelvin and Ostwald-Freundlich comparison, the saturation 
solvency can be enhanced because of the exaggerated 
dissolution coerce. 6 
This submicron colloidal molecule dispersion of drug which 
are stabilized by surfactant or concoction of surfactants is 
called as nanosuspensions. Nanosuspensions are discerned 
from nanoparticles which are polymeric colloidal carriers of 
medication, and from solid lipid nanocarriers, which are 
lipidic carriers of medication. 5 
Nanosuspension is a carrier ‑ free colloidal dosage form 
which comprises basically of arrant drug nanoparticles and 
it needs minimal measure of surfactant to stabilize them. 7 
The restriction of this precipitation method is that the 
medication should be dissolvable in no less than one solvent 
and this solvent should be miscible with antisolvent. 
Nanosuspensions are colloidal dispersions and biphasic 
framework comprising of medication scattered in an 
aqueous medium in which the width of the suspended 
particles is under 1 𝜇m in size. In bottom up method, the 
nanoprecipitation strategy confronts several benefits being 
quick and simple to accomplish. 8 
The bottom up technique is employed to formulate the 
nanosuspension on account of various merits such as 
eminent drug entrapment efficiency for poorly dissolvable 
drugs, constringe particle size distribution, extravagant 
batch-to-batch reproducibility, no necessity of 
homogenization, simple method of preparation, comfort of 
scale up and economical instruments mandatory. 9 
Generally used electrostatic stabilizers are polysorbates and 
sodium lauryl sulphate. Steric stabilizers which are normally 
used are hydroxypropyl methylcellulose, hydroxypropyl 
cellulose, polyvinylpyrrolidone, and poloxamer. 6   
The aim and objective of this study was to formulate 
ezogabine nanosuspension by bottom-up technique applying 
32 factorial design and modifying to enhance the saturation 
solubility, entrapment efficiency & dissolution rate, reduce 
the particle size, and to check stability of ezogabine. The 
three level designs are useful for investigating quadratic 
effects between the response and each of the factors.  Urea 
and surfactant concentration are used as independent 
factors.  The optimized nanosuspension formulation was 
assessed through assorted in-vitro parameters. 
MATERIALS USED 
Ezogabine was received as gift sample from Lupin Pharma, 
Maharashtra, India.  Urea is obtained as a gift sample from 
Spectrum labs, Hyderabad.  All other chemicals and solvents 
used are from Yarrow Chem Products, Mumbai. 
METHODOLOGY  
Preformulation Studies 
Compatibility Studies  
IR spectroscopy can be used to investigate and predict any 
physicochemical interactions between different components 
in a formulation and therefore it can be used for the 
selection of compatible excipient. 
Compatibility of the drug (ezogabine) with excipient (urea) 
used to produce nanosuspension was established by 
Infrared absorption spectral analysis.  I.R spectral analysis of 
pure ezogabine and urea was carried out.  This study was 
carried out to detect any changes in chemical constitution of 
drug after combining it with the excipient. 
One part of the sample and three parts of potassium 
bromide were taken in a mortar and triturated. A small 
amount of triturated sample was taken into pellet maker and 
was compressed at 10 kg/cm2 using hydraulic press.  The 
pellet was kept onto the sample holder and scanned from 
4000 cn-1 to 400 cm-1 using Perkin-Elmer spectrum RX1 
FT-IR spectrometer model. I.R spectra was compared and 
checked for any shifting in functional groups or peaks. 10 
Solubility studies of ezogabine  
Solubility of ezogabine in different solvents such as water, 
acetone, ethanol, and dimethyl sulfoxide was determined by 
shake flask method. An excess amount of ezogabine was 
added to each volumetric flask containing the selected 
vehicle and mixed thoroughly. The volumetric flasks were 
then fixed onto a water bath shaker and shaken for 24 hr at 
25 °C. Samples were removed after a specified time and 
filtered through 0.22 μm syringe driven membrane filter 
unit.  The filtrates were then analyzed by ultraviolet (UV) 
spectrophotometer at 218 nm to evaluate the amount of 
drug dissolved. 4, 11  
Method of preparation of nanoprecipitation by “Bottom 
up” Technique  
The nanosuspension was obtained by the precipitation 
process of “Bottom up” technique. The 100 mg of drug 
(ezogabine) was initially dissolved in 10 ml of polar solvent 
(ethanol) to devise the organic phase. The coded amount of 
carrier (urea) and the surfactant (sodium lauryl sulphate) 
were added to 30 ml of distilled water (antisolvent) to 
devise the aqueous phase. The organic phase was then 
slowly added drop wise using syringe into the aqueous 
phase which is kept at room temperature and stirred with a 
speed of 900-1000 rpm for 1 hr using magnetic stirrer.  
Then, the solution is homogenized for next 1 hour to remove 
excess of ethanol. 12, 13, 21 
32 Full Factorial Design  
A 32 full factorial design was applied to examine the effect of 
independent variables carrier (urea X1) and surfactant 
concentration (sodium lauryl sulphate X2) as in Table 1 on 
dependent variables such as particle size (Y1), saturation 
solubility (Y2), zeta potential (Y3), entrapment efficiency 
(Y4), and in-vitro drug release (Y5). 14 The graphs and 
mathematical models were computed using MINITAB ® 
17.1.0 (UK) software. 23 
Table 1:  Coded independent variables 
Coded Level -1 0 +1 
X1:  Carrier Concentration (mg) – Urea 10 15 20 
X2:  Surfactant Concentration (mg) - SLS 1 2 3 
 
Evaluation Characteristics of Nanosuspension 
Scanning Electron Microscopy  
Scanning Electron Microscopy has been used to determine 
particle size distribution, surface topography, texture and to 
examine the morphology of fractured surface.  Surface 
morphology of the specimens was determined by using a 
scanning electron microscope, Model JSM 84 0A, JEOI, Japan. 
The samples are dried thoroughly in vacuum desiccator 
before mounting on brass specimen studies, using double 
sided adhesive tape. Gold-palladium alloy of 120 °A Knees 
was coated on the sample sputter coating unit (Model E5 
100 Polaron U.K) in Argon at ambient of 8-10 with plasma 
voltage about 20mA. The sputtering was done for nearly 5 
minutes to obtain uniform coating on the sample to enable 
good quality SEM images.  The SEM was operated at low 
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accelerating voltage of about 15KV with load current about 
80mA. The objective lens aperture has a diameter of 240 
microns and working distance WD=39mm.  4 
Polydispersity Index  
Polydispersity Index is an index of width or spread or 
variation within the particle size distribution. Monodisperse 
samples  have  a  lower  PDI  value,  whereas  higher  value  
of  PDI  indicates  a  wider  particle  size distribution and the 
polydisperse nature of the sample. 15 PDI is calculated by the 
using following formula: 
PDI = Δd/davg 
where,  Δd  is  the  width  of  distribution  and  davg  is  the  
average  particle  size. The usual range of PDI values is as 
follows, 
Table 2:  Polydispersity Index of nanoparticles 
Polydispersity Index Type of dispersion 
0 – 0.05 Monodisperse standard 
0.05 – 0.08 Nearly monodisperse 
0.08 – 0.7 Midrange polydispersity 
˃ 0.7 Very polydisperse 
 
 
 
Saturation solubility studies 
Saturation solubility measurements were assayed through 
ultraviolet absorbance determination at 218 nm using UV-
Visible spectrophotometer (SL 210 Elico).  The process was 
carried out for both the unprocessed pure drug and different 
batches of nanosuspensions. Nanosuspension equivalent to 
100 mg of ezogabine were taken and individually hosted into 
stoppered conical flask having 10 ml of distilled water. The 
flasks were closed and retained in thermostatically 
controlled mechanical orbital shaking incubator (CIS‑24 BL, 
REMI) for 48 hrs at 37 °C and equilibrated.  The samples 
were collected after the specified time interval, filtered, 
diluted with distilled water suitably and analyzed. 5, 16 
Zeta potential analysis  
Zeta potential of the suspension is measured by Malvern 
Zetasizer using the Helmholtz-Smoluchowski equation. The 
Zetasizer mainly consists of laser which is used to provide a 
light source to illuminate the particles within the sample.  
For zeta potential measurements this light splits to provide 
an incident and reference beam.  The incident laser beam 
passes through the centre of the sample cell and the 
scattered light at an angle of about 130 is detected.  Zetasizer 
software produces a frequency spectrum from which the 
electrophoretic mobility occurs.  Hence the zeta potential is 
calculated and stability is checked by comparing with the 
Table 3. 4 
 
Table 3: Zeta potential for suspensions/emulsions and their stability 
Zeta potential (mv) Stability behaviour  
From 0 to ± 5 Rapid coagulation or flocculation 
From ± 10 to ± 30 Incipient stability 
From ± 30 to ± 40 Moderate stability 
From ± 40 to ± 50 Good stability 
More than ± 61 Excellent stability 
 
Percentage Entrapment efficiency  
The formulated nanosuspensions were centrifuged using 
cooling ultracentrifuge at 5 °C temperature and 25,000 rpm 
for 30 min.  The amount of free drug was measured by 
taking the absorbance by diluting the supernatant solution 
using UV spectrophotometer against blank/control 
nanosuspensions.  The experimentation was executed thrice 
for each batch and the mean was calculated. 17 
 
                        
                                                  
                     
 
 
In-vitro drug release studies  
In-vitro drug release studies were performed in USP 
apparatus Type II (TDT -08L, Electrolab) using paddle 
method at rotation speed of 50 rpm. Dissolution was carried 
out in pH 6.8 buffer as dissolution medium. The volume and 
temperature of the dissolution medium were 900 ml and 
37.0 ± 0.5oC respectively. Samples (5 ml) were withdrawn 
periodically at 5, 10, 15, 20 min and replaced with an equal 
volume of fresh pH 6.8.  Samples were suitably diluted and 
filtered through a filter paper (0.22 μm, Whatman Inc., USA). 
The filtrate was then subject to the UV analysis against the 
blank (pH 6.8). Percentage cumulative drug release was 
calculated based on the standard UV calibration curve at 218 
nm. 4 
Kinetics of Drug Release  
In order to analyze the drug release mechanism, in vitro 
release data were fitted into a zero-order, first order, 
Higuchi, Hixon-Crowell cube root law, and Korsmeyer-
Peppas models as in Table 4.  The zero order rate Eq. 1 
describes the systems where the drug release rate is 
independent of its concentration. 
C = kot         …………… (1)     Where, 
 C is the concentration of the drug at time (t) and ko is the 
zero-order release rate constant.  
The first order equation Eq. 2 describes the release from a 
system where the release rate is concentration dependent. 
logC = logC0 - kt / 2.303   …………..(2) 
Higuchi described the release of drugs from porous, 
insoluble matrix as a square root of time dependent process 
based on Fickian diffusion as shown in Eq. 3. 
Q = Kt
1/ 2
         .................... (3) 
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The Hixson-Crowell cube root law Eq. 4 describes the release 
from systems where there is a change in surface area and 
diameter of particles. 
Q0
1/3
 – Qt
1/3
 = KHC t …………….    (4) 
To evaluate the mechanism of drug release, data for the first 
60% of drug release were  plotted into the  Korsmeyer et al’s 
Eq. 5 as log cumulative percentage of drug released Vs log 
time, and the exponent (n) was calculated using the slope of 
the straight line. 
Mt /M∞ = Kt
n   
……………. (5) 
where  (Mt/M∞)  is  the  fractional  solute  release,  (t)  is  the  
release  time,  (K)  is  a  kinetic  constant   characteristic   of   
the   drug/polymer   system,   and   (n)   is   an   exponent   
that  characterizes the mechanism of release of tracers . 
If the exponent n = 0.45, then the drug release mechanism is 
Fickian diffusion and if 0.45 < n < 0.89, then it is non-Fickian 
or anomalous diffusion. 18 
 
Table 4: Release kinetics models 
MODELS EQUATIONS GRAPH 
Zero order Qt =Q0 + K0 t % Cumulative release Vs time 
First order Ln Qt = ln Qt + K1t Log % cumulative drug remaining Vs time 
Higuchi matrix Qt = Q0 – KH t1/2 % Cumulative release Vs √time 
Korsmeyer-Peppa’s Log (Qt / Q∞) = log K + n log t Log % cumulative release Vs  log time 
Hixon-Crowell root law Q0
1/3
 – Qt
1/3
 = KHC t Time Vs cube root % drug release 
 
Stability Studies 
Stability is defined as “The capacity of the drug product to 
remain within specifications established to ensure its 
identity, strength, quality and purity” (FDA 1987).  
Accelerated stability study was conducted to monitor the 
physical and chemical stability of Retigabine nanosuspension 
by using stability chamber at room temperature (25 °C and 
60% RH) and accelerated conditions (40 °C and 75% RH) for 
3 months according to ICH guidelines (Table 5).  Assay was 
used as the stability parameter.  At periodic time intervals, 
the samples were withdrawn and analyzed for drug content. 
18, 22 
 
Table 5: ICH guidelines for stability studies 
 
Types 
Storage Conditions Minimum Time 
Period (Months) Temperature ( °C) Humidity (%) 
Long Term Testing 25   2  60% 
 
5% RH 12 
Intermediate Testing 30  2  65% 
 
5% RH 6 
Accelerated Testing 40  2  75% 
 
5% RH 3 
 
RESULTS & DISCUSSION 
 
Fig. 2:  Standard curve of ezogabine 
The linearity was plotted for absorbance (A) against the concentration(C) with R2 value 0.999 and with the slope equation 
y=0.015x + 0.002. 
 
 
 
y = 0.0154x + 0.0024 
R² = 0.9996 
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FTIR Studies 
 
Fig. 3: FTIR of ezogabine 
 
Fig. 4: FTIR of ezogabine with Urea  
 
Table 6: Interpretation of FT-IR spectra of Pure Drug (ezogabine) 
S. No Functional Groups 
Assessment Peak of Pure Drug 
CM-1 
Range of Groups 
CM-1 
1 C-H stretching 3253.94 3333-3267 
2 C-H stretching 3005 3100-3000 
3 C-H stretching 2898 2960-2850 
4 N-H Bending 1570 1650-1580 
5 C-N Stretching 1014 1340-1020 
6 C-H Bending 797 870-675 
 
Table 7: Interpretation of FT-IR spectra of Drug & Urea 
S. No Functional Groups 
Assessment Peak of Drug & 
Urea CM-1 
Range of Groups 
CM-1 
1 N-H stretching 3348.48 3500-3300 
2 C=O stretching 1703.42 1760-1670 
3 C-H stretching 3253.94 3333-3267 
4 N-H Bending 1570 1650-1580 
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Table 8: Solubility profile of ezogabine in various 
solvents 
S. No Solvent Solubility (mg/ml) 
1 Water 0.02  
2 Acetone 25.2  
3 DMSO 27.9  
4 Ethanol 29.1  
 
Since ezogabine is poorly soluble in water and more soluble 
in ethanol when compared to other solvents such as acetone 
and DMSO, it is selected for the solubilising the ezogabine in 
nanosuspensions.  The solubility of ezogabine in ethanol is 
higher when compared to that of other solvents may be due 
to polarity character of ethanol.  
 
 
Fig. 5:  SEM analysis of F9 at 0.1μm 
 
Fig. 6:  SEM analysis of F9 at 0.5 μm 
 
The surface studies showed elongated nanoparticles with porous surface. 
Table 9: Evaluation characteristics of dependent variables 
F. 
Code 
VARIABLES RESPONSES 
X1 
Urea 
(mg) 
X2 
SLS 
(mg) 
Y1 
Particle 
size (nm) 
Y2  
Saturation 
Solubility 
(μg/ml) 
Y3 Zeta 
Potential 
(mV) 
Y4   Entrapment 
Efficiency (%) 
Y5 
In-vitro drug 
release in 20 
minutes (%) 
F1 -1 -1 582.1 392 ± 0.23 - 3.89 86.96 ± 1.85 94.32 ± 0.23 
F2 -1 0 563.5 471 ± 0.58 - 4.21 88.19 ± 0.13 95.63 ± 0.52 
F3 -1 1 541.8 528 ± 0.12 - 4.46 90.75 ± 0.32 97.86 ± 0.38 
F4 0 -1 597.2 398 ± 0.62 - 3.85 89.31 ± 0.12 97.38 ± 0.14 
F5 0 0 574.7 474 ± 0.24 - 4.17 91.76 ± 0.15 98.84 ± 0.27 
F6 0 1 551.2 534 ± 0.82 - 4.43 93.81 ± 0.51 99.91 ± 0.36 
F7 1 -1 593.3 395 ± 0.51 - 3.87 92.48 ± 0.22 99.07 ± 0.15 
F8 1 0 568.6 468 ± 0.35 - 4.23 94.53 ± 0.32 99.82 ± 0.21 
F9 1 1 510.4 557 ± 0.77 - 4.49 96.82 ± 0.14 100.14 ± 0.43 
All the above values represent mean ± S.D: n = 3 
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Particle size distribution  
The particle size was measured using a Zetasizer Nano ZS 
(Malvern Instruments, Malvern, UK). The average particle 
diameter was found to be 582 to 597 nm, 563 nm to 574 nm, 
and 510 nm to 551 nm for 1 ml, 2 ml and 3 ml of surfactant 
concentration respectively. The particle size distribution 
studies showed that the optimized formulation particle size 
was in the range 510.4 nm.  Size reduction of drug particles 
leads to an enhanced dissolution rate not only because of 
increased surface area but also because of saturation 
solubility as described by Freundlich-Ostwald equation.  All 
the formulations having a particle size in the nanometer 
range and showing ideal surface morphology. 7 
The particle size distribution studies showed that the 
optimised formulation F9 particle size was in the range 510 
nm and whereas unprocessed drug shows 50 – 60 μm in 
size. All the formulations having a particle size in the 
nanometre range and showing ideal surface morphology.  
The particle size of the formulations ranged from 510.4 nm 
to 597.2 nm.  The particle size has been decreased with 
increase in the surfactant concentration on the formulations 
irrespective of carrier concentration. The optimized 
formulation F9 showed a lowest particle size possibly 
because of highest concentration of surfactant used.  The 
carrier concentration has no significant effect on particle 
size.  The optimized formulation F9 has PDI of 0.251 
showing midrange polydispersity indicating that the 
particles are uniformly distributed. 
 
 
Fig. 7:  Particle size and Polydispersity index of F9 
Saturation Solubility Studies 
The saturation solubility studies indicates that 
nanosuspensions shows maximum solubility compared to 
unprocessed drug which is due to the crystalline nature of 
pure drug.  The saturation solubility also showed a major 
effect with increase in surfactant concentration may be due 
to the decreasing the interfacial tension between the phases.   
Approximately three times increase in saturation solubility 
of prepared nanosuspension was observed than that of 
unprocessed drug.  
  
 
Fig. 8:  Zeta potential of F9 
 
Zeta potential is related to the stability of samples.  Particles 
that are small enough with high zeta potential will confer 
stability resisting aggregation. The zeta potential of the 
prepared nanosuspension F9 was found to be - 4.49.  The 
values in the range -5 mV to +5 mV indicate fast 
aggregation/coagulation leading to drug release. 19 The 
surface charge on particles may arise due to ionisation of 
particle surface or adsorption of surfactant contributing to 
stabilisation of the nanosuspension. 20 
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Fig. 9: In-vitro drug release of F1-F9 
 
On comparing the formulations, the F9 showed 100.14% of 
drug release in 15 minutes, whereas other formulations 
required 20 minutes to yield complete drug release.  This 
may be due to the increased saturation solubility and 
decreased particle size of the formulation F9 when compared 
to that of others.  When the data of in-vitro drug release from 
nanosuspensions were fit in to different equations and 
kinetic models to explain release kinetics, the best 
formulation showed first order drug release with anomalous 
or Class II transport mechanism of drug by diffusion.  
  
Table 10: Kinetic values of F1 - F9 
F.code 
Zero-order 
plots 
First-order 
plots 
Higuchi’s 
Plots 
Korsmeyer et al’s 
plots 
Hixon-
Crowell Possible Drug Release 
mechanism 
(R2) (R2) (R2)  (n) (R2) R2 
F1 0.622 0.870 0.866 1.527 0.830 0.778 
First order Class II 
Transport 
F2 0.618 0.887 0.863 1.533 0.830 0.786 
First order Class II 
Transport 
F3 0.599 0.907 0.849 1.541 0.849 0.791 
First order Class II 
Transport 
F4 0.627 0.913 0.868 1.535 0.831 0.822 
First order Class II 
Transport 
F5 0.605 0.914 0.853 1.541 0.827 0.822 
First order Class II 
Transport 
F6 0.557 0.937 0.819 1.550 0.819 0.812 
First order Class II 
Transport 
F7 0.625 0.926 0.867 1.542 0.831 0.855 
First order Class II 
Transport 
F8 0.551 0.909 0.813 1.548 0.818 0.778 
First order Class II 
Transport 
F9 0.512 0.600 0.851 1.552 0.812 0.725 
First order Class II 
Transport 
 
Table 11:  Stability Studies Data of F9 
Storage Condition 0 Days 15 Days 30 Days 45 Days 60 Days 90 Days 
25 °C & 60 % RH 100.36 ± 0.45 97.2 ± 0.25 96.4 ± 0.67 94.1 ± 0.52 92.5 ± 0.36 91.7 ± 0.27 
Particle size 510.4 nm - 510.9 nm - 511.3 nm 511.8 nm 
40 °C & 75 % RH 98.4 ± 0.45 94.5 ± 0.75 92.1 ± 0.12 90.1 ± 0.12 86.3 ± 0.36 84.9 ± 0.19 
Particle size 510.4 nm - 519.7 nm - 528.9 nm 537.2 nm 
All the above values represent % mean± S.D: n=3 
The formulations at 25 °C remained stable, whereas only 
those stored at higher temperatures of 40 °C exhibited an 
increase in mean particle size.  The increase in size perhaps 
may be due to dehydration of the chains and subsequent loss 
of protection of the nanoparticles. Sedimentation was 
observed in all the conditions but the preparations were 
easily redispersed on shaking. 
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Table 12:  Regression coefficients for each term in the regression model 
Polynomial Equations R2 
Y1 = 564.76 - 2.29 X1_10 + 9.61 X1_15 - 7.32 X1_20 + 26.11 X2_1 + 4.18 X2_2 - 30.29 X2_3 89.16 
Y2 = 468.56 - 4.89 X1_10 + 0.11 X1_15 + 4.78 X1_20 - 73.56 X2_1 + 2.44 X2_2 + 71.11 X2_3 98.86 
Y3 = 4.17778 + 0.00889 X1_10 - 0.02778 X1_15 + 0.01889 X1_20 - 0.30778 X2_1 + 0.02556 X2_2 + 0.28222 X2_3 99.84 
Y4 = 91.623 - 2.990 X1_10 +  0.003 X1_15 + 2.987 X1_20 - 2.040 X2_1 - 0.130 X2_2 + 2.170 X2_3 99.51 
Y5 = 98.108 - 2.171 X1_10 + 0.602 X1_15 + 1.569 X1_20 - 1.184 X2_1 - 0.011 X2_2 + 1.196 X2_3 98.10 
 
From the results of ANOVA, it was observed that the 
independent factor X1 (carrier concentration) influences the 
dependent factors Y4 (entrapment efficiency) and Y5 (in-
vitro diffusion).  The independent factor X2 (surfactant 
concentration) has significant effect the dependent factors 
Y1 (particle size), Y2 (saturation solubility), Y3 (zeta 
potential), & Y5 (in-vitro dissolution) and moderate effect on 
Y4 (entrapment efficiency).   
 
Fig. 10: Contour plot of particle size Vs Urea & SLS 
 
Fig. 11: Surface plot of particle size Vs Urea & SLS 
 
Fig. 12: Contour plot of Saturated Solubility Vs Urea & 
SLS 
 
Fig. 13:  Surface plot of Saturated Solubility Vs Urea & 
SLS 
 
Fig. 14:  Contour plot of Zeta potential Vs Urea & SLS 
 
Fig. 15:  Surface plot of Zeta potential Vs Urea & SLS 
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Fig 16:  Contour plot of Entrapment Efficiency Vs Urea & 
SLS 
 
 
Fig 17:  Surface plot of Entrapment Efficiency Vs Urea & 
SLS 
 
 
Fig 18:  Contour plot of In-vitro dissolution Vs Urea & 
SLS 
 
Fig 19:  Surface plot of In-vitro dissolution Vs Urea & SLS 
CONCLUSION  
It was concluded that a simple nanoprecipitation “Bottom 
up” method can be successfully employed to produce 
ezogabine nanosuspensions. The advantage of process lies in 
it being totally free of organic solvents. The particle size of 
nanosuspension was highly dependent on parameters such 
as surfactant concentration and homogenization time.  The 
process does not alter the character of bulk ezogabine and 
marked enhancement of dissolution rate was achieved by 
the reduction in particle size and by increasing the 
saturation solubility.  The formulation F9 was found to be 
better when compared to other formulation in terms of 
particle size, saturation solubility, entrapment efficiency, 
and in-vitro drug release and was found to be stable at the 
accelerated stability conditions such as 25 ± 2 °C & 60 ± 5% 
RH 40 ± 2 °C and 75 ± 5% relative humidity for three 
months. 
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